Surpass Medical

Company Overview

Snapshot

Founded in September 2005 by Ygael Grad, Surpass Medical operated with 1–10 employees. The company was acquired by Stryker Corporation in October 2012, marking a significant exit in the medical device sector.

Business overview

Surpass Medical specializes in developing and commercializing next-generation flow diversion technology for treating brain aneurysms. Its core product, the Surpass NeuroEndoGraft, is a minimally invasive, catheter-based device designed to occlude aneurysms by redirecting blood flow, allowing the blood in the aneurysm sac to clot. The technology aims to improve efficacy in complex anatomies where traditional surgical clipping or coiling may be limited. Surpass Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics for healthcare providers.

Strategic signal

In October 2012, Surpass Medical was acquired by Stryker Corporation for $135 million. This acquisition highlights the strategic value of Surpass Medical's next-generation flow diversion technology in the neurovascular market and signals a successful exit for its investors, validating its innovative approach to treating brain aneurysms.

Company Intelligence Q&A

What is Surpass Medical's primary focus?

Surpass Medical develops and commercializes next-generation flow diversion technology to treat brain aneurysms using a unique mesh design and delivery system.

When was Surpass Medical founded?

Surpass Medical was founded in September 2005.

Who founded Surpass Medical?

Surpass Medical was founded by Ygael Grad.

What is the key product offered by Surpass Medical?

The company's key product is the Surpass NeuroEndoGraft, a device designed to occlude brain aneurysms by redirecting blood flow.

What was a significant corporate event for Surpass Medical?

In October 2012, Surpass Medical was acquired by Stryker Corporation for $135 million.